Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer

NCT00005970 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00005970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00005970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Completed
Start date
May 19, 2000
Completion date
January 27, 2010
Enrollment
3,436 (actual)
Sites
157

Conditions

As the registry lists them; a condition with its own page is linked.

breast adenocarcinoma, her2 positive breast carcinoma, stage ia breast cancer ajcc v7, stage ib breast cancer ajcc v7, stage iia breast cancer ajcc v6 and v7, stage iib breast cancer ajcc v6 and v7, stage iiia breast cancer ajcc v7